Treat-and-extend Using Aflibercept for Type 3 Neovascularization

NCT04655482 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Retinal Angiomatous Proliferation

Interventions

DRUG: Aflibercept Injection

Sponsor

Kim's Eye Hospital

Collaborators

[object Object]